Safety and efficacy of once-weekly semaglutide in the initiation and switching from other GLP-1RA in patients with type 2 diabetes
Not Applicable
- Conditions
- Diabetes Mellitus
- Registration Number
- JPRN-UMIN000041000
- Lead Sponsor
- Murakami Memorial Hospital
- Brief Summary
Total HbA1c0week7.24,16week6.80(%) GA0week15.9,16week14.3(%) Body weight0week82.46,16week76.77(kg) Add on OHA group(A)HbA1c 0week7.18,16week6.74(%),Change from another GLP-1RA(G)HbAc0week7.29,16week6.585(%),G Body weight 0week81.69,16week79.14(kg) HbA1c significant reduction and Body weight loss using SEmaglutide.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 49
Inclusion Criteria
Not provided
Exclusion Criteria
Severe renal impairment (eGFR<30ml/min/1.73m2, end stage at CKD and dialysis) (dialysis and eGFR less than 30 ml/min)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of gastrointestinal disorders adverse events for 16 weeks Change in HbA1c, body weight, and GA from baseline to 52 weeks
- Secondary Outcome Measures
Name Time Method Frequency of blood glucose confirmed hypoglycemia(<70 mg/dL)at 16 and 52 weeks Change in CPR and FPG at 16 and 52 weeks Effects on body composition at 16 and 52 weeks Change in HbA1c and body weight at week 16 and 52 by pretreatment and patient background